Press Room - Sanofi US News

Media Room Menu

Feb 6, 2019

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder
Jan 28, 2019

Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)

Provention is currently developing PRV-101 as a polyvalent vaccine for acute coxsackie virus infection and to potentially prevent the onset of T1D
Jan 23, 2019

FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age

- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age
Jan 17, 2019

FDA advisory committee votes on Zynquista™ (sotagliflozin) as treatment for adults with type 1 diabetes
Jan 14, 2019

FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination

* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)

Show per page